AVANOS MEDICAL (NYSE:AVNS) Given “Sell (D-)” Rating at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of AVANOS MEDICAL (NYSE:AVNS) in a research note published on Tuesday,Weiss Ratings reports.

A number of other equities research analysts have also commented on AVNS. Wall Street Zen lowered shares of AVANOS MEDICAL from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 9th. Zacks Research upgraded shares of AVANOS MEDICAL to a “hold” rating in a report on Tuesday, August 12th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, AVANOS MEDICAL has an average rating of “Reduce”.

AVANOS MEDICAL Price Performance

Shares of AVANOS MEDICAL stock opened at $10.98 on Tuesday. AVANOS MEDICAL has a 52-week low of $9.30 and a 52-week high of $23.68. The stock has a market capitalization of $509.66 million, a price-to-earnings ratio of -1.09 and a beta of 1.15. The company has a fifty day moving average of $11.61 and a 200-day moving average of $12.10. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.58 and a current ratio of 2.64.

AVANOS MEDICAL (NYSE:AVNS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). AVANOS MEDICAL had a negative net margin of 66.89% and a positive return on equity of 6.16%. The business had revenue of $175.00 million during the quarter, compared to analysts’ expectations of $165.50 million. During the same period last year, the company posted $0.34 EPS. AVANOS MEDICAL has set its FY 2025 guidance at 0.750-0.950 EPS. Equities research analysts expect that AVANOS MEDICAL will post 1.32 EPS for the current year.

Insider Buying and Selling

In related news, Director Gary Blackford acquired 40,000 shares of the firm’s stock in a transaction on Wednesday, August 13th. The stock was acquired at an average cost of $10.99 per share, for a total transaction of $439,600.00. Following the acquisition, the director owned 40,000 shares of the company’s stock, valued at $439,600. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 2.64% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in AVNS. Armistice Capital LLC bought a new position in AVANOS MEDICAL in the 1st quarter worth $28,660,000. T. Rowe Price Investment Management Inc. grew its position in shares of AVANOS MEDICAL by 24.8% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,757,576 shares of the company’s stock worth $53,847,000 after buying an additional 746,264 shares during the period. Clark Estates Inc. NY purchased a new stake in shares of AVANOS MEDICAL in the 1st quarter worth about $7,077,000. Millennium Management LLC grew its position in shares of AVANOS MEDICAL by 508.3% in the 1st quarter. Millennium Management LLC now owns 547,740 shares of the company’s stock worth $7,849,000 after buying an additional 457,703 shares during the period. Finally, Pacer Advisors Inc. purchased a new stake in shares of AVANOS MEDICAL in the 1st quarter worth about $6,056,000. 95.17% of the stock is currently owned by institutional investors.

About AVANOS MEDICAL

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.